18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer

被引:155
作者
Komar, Gaber [1 ]
Seppaenen, Marko [1 ]
Eskola, Olli [1 ]
Lindholm, Paula [2 ]
Groenroos, Tove J. [1 ]
Forsback, Sarita [1 ]
Sipilae, Hannu [1 ]
Evans, Sydney M. [3 ]
Solin, Olof [1 ]
Minn, Heikki [1 ,2 ]
机构
[1] Turku PET Ctr, FIN-20521 Turku, Finland
[2] Univ Turku, Dept Radiotherapy & Oncol, Turku, Finland
[3] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
关键词
head and neck cancer; hypoxia; F-18-EFS; squamous cell carcinoma;
D O I
10.2967/jnumed.108.053785
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to evaluate 2-(2-nitro-H-1-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5) labeled with F-18-fluorine to image hypoxia in patients with squamous cell carcinoma of the head and neck (HNSCC). Methods: Fifteen patients with HNSCC were studied. Measurement of tumor blood flow was followed by an F-18-EF5 PET/CT scan. On a separate day, F-18-FDG PET/CT was performed to determine the metabolically active tumor volume. In 6 patients, dynamic F-18-EF5 images of the head and neck area were acquired, followed by static images acquired at 1, 2, and 3 h after injection. In the remaining 9 patients, only static images were obtained. F-18-EF5 uptake in tumors was compared with that in neck muscle, and the F-18-EF5 findings were correlated with the F-18-FDG PET/CT studies. Results: A total of 13 primary tumors and 5 lymph node metastases were evaluated for their uptake of F-18-EF5. The median tumor-to-muscle F-18-EF5 uptake ratio (T/M) increased overtime and was 1.38 (range, 1.1-3.2) 3 h after tracer injection. The median blood flow in tumors was 36.7 mL/100 g/min (range, 23.3-78.6 mL/100 g/min). Voxel-by-voxel analysis of coregistered blood flow and F-18-EF5 images revealed a distinct pattern, resulting in a T/M of 1.5 at 3 h to be chosen as a cutoff for clinically significant hypoxia. Fourteen of 18 tumors (78%) had subvolumes within the metabolically active tumor volumes with T/M greater than or equal to 1.5. Conclusion: On the basis of these data, the potential of F-18-EF5 to detect hypoxia in HNSCC is encouraging. Further development of F-18-EFS for eventual targeting of antihypoxia therapies is warranted.
引用
收藏
页码:1944 / 1951
页数:8
相关论文
共 38 条
[11]  
EVANS SM, 1966, INT J RAD ONCOL BI S, V66, pS248
[12]   Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome [J].
Evans, Sydney M. ;
Du, Kevin L. ;
Chalian, Ara A. ;
Mick, Rosemarie ;
Zhang, Paul J. ;
Hahn, Stephen M. ;
Quon, Harry ;
Lustig, Robert ;
Weinstein, Gregory S. ;
Koch, Cameron J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04) :1024-1031
[13]  
Grönroos T, 2004, EUR J NUCL MED MOL I, V31, pS384
[14]   Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer [J].
Grosu, Anca-Ligia ;
Souvatzoglou, Michael ;
Roeper, Barbara ;
Dobritz, Martin ;
Wiedenmann, Nicole ;
Jacob, Vesna ;
Wester, Hans-Juergen ;
Reischl, Gerald ;
Machulla, Hans-Juergen ;
Schwaiger, Markus ;
Molls, Michael ;
Piert, Morand .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (02) :541-551
[15]   Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects [J].
Höckel, M ;
Vaupel, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :266-276
[16]  
Kaanders JHAM, 2002, CANCER RES, V62, P7066
[17]  
Koch CJ, 2002, METHOD ENZYMOL, V352, P3
[18]  
Koch CJ, 2001, CANCER CHEMOTH PHARM, V48, P177
[19]  
Krause BJ, 2006, Q J NUCL MED MOL IM, V50, P28
[20]  
Laughlin KM, 1996, J PHARMACOL EXP THER, V277, P1049